Medium-chain triglycerides improve cognition and systemic metabolism in mouse models of Alzheimer’s disease - Top-Institutions - MDSpire

Medium-chain triglycerides improve cognition and systemic metabolism in mouse models of Alzheimer’s disease

  • By

  • Paule E H M’Bra

  • Laura K Hamilton

  • Gaël Moquin-Beaudry

  • Chenicka L Mangahas

  • Federico Pratesi

  • Anne Castonguay

  • Sophia Mailloux

  • Manon Galoppin

  • Jessica Avila Lopez

  • Megan Bernier

  • Marta Turri

  • Marian Mayhue

  • Anne Aumont

  • Martine Tetreault

  • Stephen C Cunnane

  • Karl J L Fernandes

  • August 6, 2025

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Neuroscience
    • Metabolic Research
    • Alzheimer's Disease

  • #2

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Neuroscience
    • Metabolism
    • Alzheimer's Disease

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Neurodegenerative Diseases
    • Metabolic Disorders

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Neuroscience
    • Metabolic Research

  • #5

    University of Toronto
    University of Toronto

    Toronto, ON

    Key Differentiators

    • Neurology
    • Metabolic Research
    • Alzheimer's Disease

Original Source(s)

Medium-chain triglycerides improve cognition and systemic metabolism in mouse models of Alzheimer’s disease

  • by Paule E H M’Bra, Laura K Hamilton, Gaël Moquin-Beaudry, Chenicka L Mangahas, Federico Pratesi, Anne Castonguay, Sophia Mailloux, Manon Galoppin, Jessica Avila Lopez, Megan Bernier, Marta Turri, Marian Mayhue, Anne Aumont, Martine Tetreault, Stephen C Cunnane, Karl J L Fernandes

  • August 6, 2025

Related Content

High-Level Alzheimer Disease Neuropathological Change Following Iatrogenic Exposure

Glial Fibrillary Acidic Protein and Neurofilament Light Reference Intervals in Healthy Individuals

Acceptability of Technologies to Support Early Dementia Detection: Qualitative Study With the Boston University Alzheimer’s Disease Center Cohort